11 May 2023
-
The health and pharmaceutical industry is a high-stakes game, where the pressure to innovate and produce groundbreaking products is immense. Developing new drugs is only part of the equation - companies must also create "blockbusters" that set them apart from the competition. In this article, Sentadell Associates provides analysis and insight into how the concept of BlockBusters drives innovation in the pharmaceutical industry.
To begin this article, there needs to be an understanding of what a concept or the term "blockbuster" is. In the world of pharmaceuticals, a drug that generates annual sales of $1 billion or more is commonly referred to as a "blockbuster." These drugs are often developed after extensive research and development efforts, and are used to treat widespread or chronic health conditions, providing significant benefits to patients while also generating substantial revenue for pharmaceutical companies.
To further delve in, the key in understanding the impact of this concept in the pharmaceutical world is initially knowledge about activity and spending in the world of R&D of the pharmaceutical industry. In the highly competitive and rapidly evolving field of pharmaceuticals, R&D is essential for companies to remain at the forefront of innovation. By investing in drug discovery, pre-clinical testing, clinical trials, and regulatory approval, pharmaceutical companies can create new drugs that improve patient outcomes and deliver significant value to shareholders. Moreover, the total expenditure for R&D by pharmaceutical companies worldwide in 2022 was USD238 billion, reflecting an increase of approximately 22.79% from the amount spent in 2019, which was USD192 billion. This increase reflects the continued commitment of pharmaceutical companies to research and development of new drugs and treatments. This increase was be due to several factors, including advancements in technology and scientific knowledge, increasing demand for innovative treatments for various diseases, and the need to address emerging health challenges such as the COVID-19 pandemic.
In the midst of progress and advancement since 2019 especially in R&D, pharmaceutical companies have focused their resource allocation on developing vaccines and treatments for the COVID-19 pandemic. Thus, let’s take a look at recent blockbuster breakthrough, namely Cominarty Vaccine. The emergence of Comirnaty, the Covid-19 vaccine developed by Pfizer, can be regarded as a significant breakthrough and a highly successful blockbuster, given that Pfizer held a virtual monopoly over it. With its diverse range of products, Pfizer has a strong presence in a variety of specialties, such as Cardiovascular (Eliquis), Oncology (Ibrance), and vaccines including Comirnaty and the Prevnar family. Morever in addressing this phenomenal emergence, this particular blockbuster is the first mRNA vaccine to receive emergency use authorization by the United States Food and Drug Administration (FDA), marking a major milestone in the development of vaccines for infectious diseases with the direct sales revenue of USD 41.6 million in 2020 doubled (100%) in the following year, reaching an astonishing USD 81.2 million in 2021 with the highest proportion for the sale of its covid-19 vaccine.
The analysis of vaccine distribution data in Europe by Sentadell Associates above indicates that the Comirnaty vaccine, which was created through the collaboration of Pfizer and BioNTech, has attained the highest level of penetration and distribution throughout the EU region, outpacing leading competitors such as AstraZeneca, Moderna, and J&J. This means that the emergence phenomenon and the discovery of this blockbuster drug have given Pfizer an unprecedented push and a remarkable record for a pharmaceutical company's research accomplishment.
According to the data analysis by Sentadell Associates, one factor that has strengthened the dominance of vaccines as blockbusters is the findings that Pfizer and BioNTech have secured production of their COVID-19 vaccine in 164 million doses. These doses were obtained through bilateral agreements with countries such as Kazakhstan, Taiwan, Japan, Hong Kong, Albania, Vietnam, the Philippines, and Argentina. The analysis data above demonstrates that Pfizer and BioNTech have been successful in securing agreements for a significant number of COVID-19 vaccine doses, which has contributed to their dominance as a leading producer of blockbuster drug such as COVID-19 vaccines.
Developing drugs in the pharmaceutical industry is a lengthy process that often involves rigorous regulatory approval processes lasting for ten years or more. Nevertheless, companies like Pfizer have managed to produce remarkable drugs like Comirnaty that can quickly become blockbuster hits in the healthcare market. These breakthroughs have had a notable impact on the investment world, particularly in the context of pharmaceutical assets. For instance, Pfizer's stock price rose by 71% from USD 29.66 to $50.77 between March 2020 and December 2022, reflecting the success of these breakthroughs.
In conclusion, the pharmaceutical industry's drive to create blockbuster drugs has led to remarkable breakthroughs and significant advancements in healthcare. The intense competition among pharmaceutical companies has driven substantial investment in research and development, resulting in impressive revenue generation and significant benefits for patients worldwide. The emergence of Comirnaty, the Covid-19 vaccine developed by Pfizer, is an excellent example of a highly successful blockbuster drug that has delivered significant value to both patients and shareholders. This has driven the dominance of vaccines as blockbusters, with Pfizer and BioNTech securing agreements for a significant number of COVID-19 vaccine doses. This achievement has significantly impacted the investment world, with Pfizer's stock price rising substantially in the last two years. As such, blockbuster drugs remain a driving force behind innovation and growth in the pharmaceutical industry, and the race to create the next blockbuster drug continues.
Back to Insight
